hVIVO has reported full-year 2025 results against a tougher market backdrop, while continuing to reposition the business and integrate acquisitions. In this interview, CEO Mo Khan discusses the headline financials, the performance of the core human challenge trial business, the pressures faced during the year, and what investors should be looking for in 2026.
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
